Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

Celcuity’s stock jumps after Phase 3 trial shows gedatolisib slashes progression risk in breast cancer patients by up to 76%.

Celcuity ( ($CELC) ) has issued an announcement. On July 30, 2025, Celcuity Inc. entered into an underwriting agreement with several underwriters ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Celcuity (NASDAQ:CELC) has announced the pricing of two underwritten public offerings. The first is a $175 million offering ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...